🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sotera Health Company (SHC)
NASDAQ: SHC · Real-Time Price · USD
16.28
+0.22 (1.40%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

A global sterilization and testing platform targets 5%–7% annual revenue growth in 2025–2027 and is prioritizing customer integration, capacity expansion and sterilization-focused M&A. Q4 2026 Sterigenics growth was guided at 6% constant currency amid European MedTech softness; 2027 lower capex is expected to accelerate cash flow.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

All right, getting the thumbs up. I am Dave Windley with Jefferies Healthcare Equity Research. I cover the pharma services and outsourcing space for Jefferies. Very pleased and gratified to have you folks here supporting our conference. Lost track of the number of years, but it seems like a lot, and it does keep growing. In the audience here in person, but also listening on the webcast, I want to introduce our next speaker. Representing Sotera Health is Alton Shader, the company's CEO of not that long, but settling in quite nicely. We are going to do a little hybrid style here, so he is going to make some prepared remarks, and then we will ask a few questions. Alton, I will turn it over to you.

Alton Shader
CEO, Sotera Health Company

Thank you very much. Appreciate it, and thank you all for joining us here today. I appreciate you all taking the time to learn more about Sotera Health. Before we get into the presentation, just wanted to mention that some of the statements I make today may be considered forward-looking. Please refer to our SEC filings for a description of the risks and uncertainties that could cause our actual results to differ materially from these projected or implied. The company assumes no obligation to update forward-looking statements. During this presentation, we may talk about certain non-GAAP financial measures. Again, please refer to our SEC filings for a reconciliation of these measures. Again, very happy to be here with you today. I am going to hit on three key topics when discussing Sotera Health. The first is the crucial role we play in the healthcare industry.

I then will move on to a review of our financial profile and the resilience of our business over time. Then I am going to walk through our path to creating value for our key stakeholders, including our customers as well as our investors. To really understand the Sotera Health story, you need to recognize the criticality of the services that we provide to our customers every day. Every year, our services touch billions of medical products, and we allow the safe delivery of these billions of products to hundreds of millions of patients worldwide, again, every year. To bring that more closer to home, if you or a loved one has had any sort of procedure or surgery over the course of the last year, if you have been administered an influenza vaccine, if you rely on insulin to help treat your diabetes.

There is a pretty good chance that Sotera Health has touched your life over the course of the last year. Again, it is something that we are very committed to. Our mission is safeguarding global health, and the way that we attack that mission and live that mission every day is we provide end-to-end solutions to our customers in highly regulated markets like healthcare. We serve customers in 50 countries around the world, and our 3,000+ associates are within our 63 facilities around the world, and we cover 13 countries with those facilities. Because we are such strong partners and have an essential role in healthcare, we have partnerships with over 40 of the top 50 med device customers or companies in the world, and we partner with nine of the top pharma companies in the world. We also, again, have very close partnerships with our customers.

Over 70% of our customers have multi-year contracts, and of our top 25 customers, we have an average of over 15-year tenure working with those customers. Again, partnership is critical for us. We are a service company, and ensuring we have those trusted partnerships is critical. We have also shown a strong track record of cash generation as well as a disciplined capital allocation approach, and I will speak more to both of those here in a bit. How do we go to market? We go to market in three specific business units. The first is our largest business, Sterigenics. Sterigenics is a global leader in comprehensive sterilization solutions. What we do at Sterigenics generally is mandated by regulatory authorities, so it is absolutely critical to providing safe healthcare products to care teams and patients around the world.

We have over 2,000 customers that rely on us every single day for high-quality and safe delivery of their products. We have a broad set of modalities that we provide for sterilization, including gamma sterilization, which is Cobalt-60, EO, also E-beam, as well as X-ray modalities. Our Nordion business is the world's largest supplier of Cobalt-60 sealed sources. This is critical because Cobalt-60 is the radioisotope that allows gamma sterilization, as you can see in the chart here, that is identified as Cobalt-60 sterilization. This is critical because about 30% of medical devices each year are sterilized with gamma sterilization.

Nelson Labs is a global leader in microbiological as well as analytical lab testing. We have got over 3,000 customers around the world. We provide 900+ tests to our customers, and this is a very complementary business to our Sterigenics business. Overall, this is how we go to market, and again, absolutely essential services that we provide to the healthcare market. I will now move on to our financial profile, and we have demonstrated a strong record of performance since we have gone public in 2020. You can see our top-line CAGR has been 7% over this time. Our EBITDA CAGR has been 7% as well. I will highlight the fact that we are a very profitable company. We have got a 51% EBITDA margin, which we have maintained over this time. We have also been successful in growing our free cash flow.

You can see in 2020 vs the trailing 12 months here at the end of calendar Q3 2026, we have more than doubled our free cash flow growth. I will also comment on the fact that we have an extremely resilient business. Over the course of the last 20 years, we have grown our top line every single year, no matter what the economic circumstances or situations were. Through the recession of 2008/ 2009 through COVID, through the supply chain crisis post-COVID, we were able to grow our business in each of those years. Now, moving on to how we drive value again for both our customers as well as our investors. We have got four key priorities within our company. The first is to delight our customers with end-to-end solutions.

As I mentioned, we are primarily a service company, and it is absolutely critical as a service company that we delight our customers and we are able to build, again, stronger and trusted relationships with those customers. The end-to-end solution is also a critical differentiator for our business, particularly with Sterigenics and Nelson Labs, to be able to offer an integrated sterilization, validation, and testing protocol for our customers. We also need to win in growth markets with our customers, and we need to drive operational excellence to continue to enhance our free cash flow. We also need to continue to have a disciplined capital deployment methodology, and our focus as we move forward is to continue to have strong execution across these key priorities. Again, this serves our stakeholders as we move forward here. Let's start with customers and how we deliver value to customers.

We work with our MedTe ch customers from the beginning to the end of their product life cycle. When they are in the design and development phase, we are working with them with testing, we are providing sterilization validations. As that product moves closer to commercialization and is launched, we continue to provide a number of services, both from Sterigenics as well as Nelson Labs, and this continues as the product is marketed. What we do and what we are focused on with our customers is providing them a high level of confidence in our services, but also allow them to be in compliance. We are always focused on a very high quality and reliable execution of all of our services, and we also are leaned upon heavily from our customers due to our technical and regulatory expertise.

We also have a purpose-built network of 49 sterilization facilities and 11 laboratories. Again, Nelson Labs has over 900 tests that they offer to our customers, and this is incredibly important. I will speak to the sterilization aspect of this. Our customers want our sterilization facilities near their manufacturing or their distribution centers. Having scale in this business is incredibly important, and the team, again, has built this purpose-built network, really to serve our customers at the top level. We also have a number of cross-business unit synergies that we are actively pursuing. Today, Sterigenics and Nelson Labs, if you combine the revenue of those two businesses, 70% of that revenue is with shared customers. We have a real opportunity to embed ourselves even more deeply with our customers, take advantage of the strong relationships we have either within Sterigenics or Nelson Labs.

Again, what is key to our success is being able to offer these end-to-end solutions and also simplifying the customer experience. We do operate with three business units, but we want to go to market as one Sotera Health and ensure that we are bringing the full value of our full set of capabilities to our customers. Now, moving to our revenue targets. In 2024, at our investor conference, we outlined our growth goals for the business. From 2025 through 2027, we have a growth goal top line of 5%-7% for Sotera Health, and this is inclusive of a 3%-4% price impact per year. This translates for Sterigenics into a mid to high single digits growth rate per year, Nordion, a low to mid single digits growth rate, and Nelson Labs, a mid- single digits growth rate.

With respect to pricing, we expect Sterigenics to be at the higher end of that 3%-4% annual pricing range, and we expect Nordion and Nelson Labs to be at the lower end of that range. Now, moving to capital allocation. Obviously, it is incredibly important for us to maintain a healthy balance sheet, and we have done a nice job of continuing to build health here. We are currently operating at a 2.9x Net Leverage Ratio, which is within our target of 2x-3x. The team has also done a very nice job of delevering over time through growth, and we have also seen improved credit ratings. Now, when it comes to our prioritization around capital allocation, our first priority is around organic growth investments.

To get into more detail there, the top tier for our organic growth investments is around expanding the capacity we already have within our facilities. So, if you can add a chamber, for example, within our sterilization facilities. Next would be adding additional square footage within those specific facilities we already have, based on the amount of demand that we are seeing from our customers within that facility. We then would next move to the organic investment in greenfield builds, like the X-ray facility that came online in Q3, and a new facility that we have coming online in Q1 2028. As we move to the next level of prioritization with our capital deployment, we see more opportunistic opportunities. The first is around value-accretive and strategic M&A, and our focus area here is around the Sterigenics business and sterilization services.

We also are in communication with our Board, constantly talking about other uses of capital, including potential debt reduction as well as potential share repurchases, although I will note we do not have an authorization for share repurchases. So, disciplined capital deployment, absolutely critical for our business and important for us as we continue to drive long-term shareholder value. Now, as Dave mentioned, I have not been with the company too long. I have been with the company now for a little under six months, and I am incredibly excited about the opportunities that we have as a business. We are a leader in an incredibly attractive space that is growing. We have a high level of expertise on the technical side, regulatory side, that our customers lean on us every day to provide value as a key partner.

We have a global network that, again, is purpose-built and is in proximity to where our customers are operating, which allows us to build stronger relationships with them. We have an end-to-end platform that we continue to leverage, and we are working hard to ensure we have a one Sotera approach to all of our customers to ensure that we are providing the value that they are looking for and allow them to attack the opportunities they have and address any issues they may have. We are positioned for above-market growth as we go forward. We have an incredibly strong and consistent financial profile with consistent top-line, bottom-line growth. We expect our free cash to continue to grow. We are at a high watermark for our capital investment here in 2026.

We expect that to meaningfully decrease in 2027, which will lead to accelerating cash flow in addition to improved EBITDA. We will continue to have a disciplined capital allocation approach as we go forward. As we continue to execute across these areas, I think we are well-established and ready to continue our success in the future. Thank you again for your time, and now I'll sit down with Dave and answer some of his questions.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

All right.

Alton Shader
CEO, Sotera Health Company

Thanks, Dave.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Thank you for that.

Alton Shader
CEO, Sotera Health Company

Yep.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Let me start you off a little bit pretty close to where you ended around growth and strategic actions. I believe in some of your commentary, you've actually alluded to a, quote-unquote, "next leg of growth." Perhaps that's something you have your eye on, perhaps the board telling you to have your eye on. How do you think about what that might be? You named off a number of areas of kind of organic investment.

Alton Shader
CEO, Sotera Health Company

Yep.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

EO, Cobalt-60 supply, sterilization capacity, greenfields, EO updates, et c. What thoughts are in your mind or factors that drive your considerations around that, quote, "next leg of growth"?

Alton Shader
CEO, Sotera Health Company

Sure. To clarify that next leg of growth, we are not actively pursuing a fourth leg, if you will. When we are evaluating growth opportunities, it is within the markets that we're playing today and within the capability sets that we have within Sterigenics, Nelson Labs, and Nordion. That's one point. I do believe that we have a significant opportunity for organic growth in our business, and it's in a few areas where we need to execute. The first is ensuring that we have this one Sotera approach, ensuring that we've got a differentiated offering that takes advantage of the broad set of capabilities that we have, particularly in Sterigenics as well as Nelson Labs. That's the first piece. The next piece is we need to ensure that we're doing a better job of coordinating all of these services within our accounts.

We've got to not only have an offering that is differentiated, but ensure that we're operating as one company and that we're very easy to work with, based on how we are going to market and working with our key customers. Lastly, it's around execution. We are, again, a service-based company. The best way to earn more business in a service company is to be able to execute, and for us, that means ensuring that we have high-quality services that are incredibly reliable, that we have best-in-class turnaround time, and we have best-in-class on-time delivery as well. If we can execute across those three, we are going to see strong growth within our business.

In addition, if we move to inorganic growth, as I mentioned a bit before, we are evaluating M&A opportunities, and this is an area where we are active, and we are primarily focused in the sterilization services part of our business today.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Within sterilization, I think MedT ech is the predominant area of focus, but bioprocessing and some of the life sciences areas are also there for both you and primary competitor. Is it different end markets? How should we think about adjacencies that would stay within the three businesses, but expand?

Alton Shader
CEO, Sotera Health Company

I think, again, for us, if you're speaking primarily inorganically, is that right?

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Right. Yes.

Alton Shader
CEO, Sotera Health Company

Yeah, inorganically, we would be more focused on really the core sterilization. What we would do is we're looking for assets that make sense for us to own. So, assets where we believe that we can add value once they become a part of Sotera Health. So, when you're looking at sterilization assets, it's not as easy to find an asset that is focused on one specific end market. So, again, we're looking at this more generally, and we're also looking obviously across geographies as well.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Got it. The I'm trying to think of your service provision in MedT ech seems fairly well covered. What might be the adjacencies that you would view as underbuilt that an acquisition could help to augment? Would geography be the right axis to think?

Alton Shader
CEO, Sotera Health Company

Absolutely. Geography is definitely one axis to think about. That's near the top of our list. That said, if we are already operating in a geography and there is a sterilization provider who has a significant amount of capacity, and we believe that our customer relationships can help improve the utilization, and we could potentially manage that facility and that business more effectively, then that is definitely something that we would consider.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Okay. Let's pivot a little bit to a little more near-term tactical. On the third quarter call, you had highlighted some, say, moving demand trends, particularly over here in Europe. Your Sterigenics business has had quite strong growth year- to- date, I think over 8% constant currency. You are also saying that it looks like the sequential progression might be a little flat. What are you seeing underneath? Take us down a layer on what are you seeing in that softness? Is there a finer point you can put on those issues? It has only been, what, a week or two since your earnings release, but what have you been able to assess about whether this is temporary or longer-lasting?

Alton Shader
CEO, Sotera Health Company

Sure. First, we are very pleased with Sterigenics' performance in Q3, 8.2% constant currency growth. Team did a really nice job of serving their customers throughout the quarter. We did notice some softness near the end of Q3, and that softness did extend into the first couple weeks of Q4. Obviously, we guided Sterigenics to a 6% constant currency growth for Q4, which was a little bit lower than expectations. I will make the point that we are expecting sequentially that business to be flat. Q3, Q4 Sterigenics is going to be flat. We are not seeing a massive decline in demand at this point. What we are seeing is a relatively small impact. However, it did impact us.

When we get into more details around the softness, we did see some softness in the U.S., but a majority of the softness and a majority of the decline in growth from the business was in Europe, and it was focused on our MedT ech segments. When we got into more detail on that, it was a pretty mixed bag. It was not a general 1%-2% volume decline across all the segments. Some segments were growing, some segments were not growing. When you put that all together and you looked at our business and the impact, it did have this impact on volume, which again, is captured in that 6% constant currency growth and that sequential flat revenue quarter-over-quarter.

Overall, we see a pretty stable environment for demand for the business, but again, we did see some of that softness here at the beginning of Q4.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Coming away from the numbers and just thinking about cadence and timing, what are your clients' planning cycles such that the information comes out the backside of that to you that then informs how you think you might step into 2027?

Alton Shader
CEO, Sotera Health Company

Yeah. We're pretty aligned with our customers around their planning cycles, right? We're working with them right now on their 2027 plans, which will inform our 2027 plan and our budget, which we're in the midst of today. But in general, we've got pretty good visibility with Sterigenics business, for example. However, when our customers see a change in demand, we see that pretty quickly. There is a short cycle nature to the business. But overall, we're working close with our customers, and we look forward to ensuring that we've got the right plan in place for 2027.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Okay. Let's squeeze in a margin question here quickly. I think the three-year plan, the 2025 to 2027 plan, looked for 50 basis points- 150 basis points of expansion. Already close to that at the high end. Mix is certainly something that can have an influence on margin, but I'm kind of trying to isolate that and set that aside. What other levers are you looking to pull as you continue to expand margin?

Alton Shader
CEO, Sotera Health Company

Yeah. A couple points. One, we're on track for that 50 basis points- 150 basis points margin improvement that we discussed at the end of 2024 in the 2025 to 2027 planning period. We delivered 118 basis points of margin improvement in 2025. We do expect our margins in 2026 to be flat for the business full year, and the primary driver of that is Nelson Labs. Even though we've got improved margin year- over- year in both Nordion and Sterigenics, we expect Nelson Labs margin to be between 30% and 31% here in 2026. So that's contributing to our flat EBITDA margin in 2026. The levers we have going forward, we've got a number of levers. I think primarily it is volume is critical for us, right? We have a high amount of fixed costs within our business.

If we can continue to, again, delight our customers, provide them with the solutions that they need, that is going to drive volume for us, and that is going to have an outsized impact on our EBITDA. In addition, we need to continue to push productivity measures operationally. If we execute on both of those, we should see some positive margin impact.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Excellent. All right. I think we are over time, and I see my colleague peeking in, so time to turn it over to the next session. Thank you for being here.

Alton Shader
CEO, Sotera Health Company

Thank you.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Thanks to the audience for your attention.

Alton Shader
CEO, Sotera Health Company

Thanks.

Dave Windley
Healthcare Equity Research Analyst, Jefferies

Thank you, sir.